66826-78-6

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2,3-dihydro-1-benzofuran is used as an organic building block for the synthesis of Darifenacin (D193400), a drug specifically designed to treat urinary incontinence. 5-Bromo-2,3-dihydro-1-benzofuran plays a crucial role in the development of medications targeting the management of involuntary urination, improving the quality of life for affected individuals.

InChI:InChI=1/C8H7BrO/c9-7-1-2-8-6(5-7)3-4-10-8/h1-2,5H,3-4H2

Upstream product

• 34743-88-9 2-(4-bromophenoxy)ethanol 
• 18800-30-1 1-bromo-4-(2-bromoethoxy)benzene 
• 496-16-2 2.3-dihydrobenzofuran 
• 76429-66-8 β-(2,4-Dibromophenoxy)ethyl Bromide 
• 377091-18-4 1,4-dibromo-2-(2-bromoethoxy)benzene 
• 1435-52-5 2,5-dibromofluorobenzene 
• 377091-17-3 1,4-dibromo-2-hydroxyethoxybenzene 
• 64010-12-4 2-bromophenyl 2-chloroethyl ether 
• 615-58-7 2,4-dibromophenol 
• 106-41-2 4-bromo-phenol 

Downstream Products

• 40492-52-2 2,3-dihydrobenzofuran-5-ol 
• 23145-07-5 5-bromobenzofuran 
• 55745-70-5 2,3-dihydro-benzofuran-5-carbaldehyde 
• 281678-73-7 5-bromo-2,3-dihydrobenzo[b]furan-7-carboaldehyde 
• 227305-69-3 2,3-dihydrobenzofuran-5-boronic acid 
• 203505-84-4 3-(2,3-dihydro-1-benzofuran-5-yl)-2-propenoic acid 
• 76429-68-0 5-methyl-2,3-dihydrobenzofuran 
• 1447730-81-5 (S)-5-((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)-2,3-dihydrobenzofuran 
• 1447730-82-6 5-((1S,5S)-2-methylene-5-(prop-1-en-2-yl)cyclohexyl)-2,3-dihydrobenzofuran 

Relevant academic research and scientific papers

Synthesis, evaluation and in silico studies of novel BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold

Abstract: The BRD4 protein is associated with various diseases, which has been an attractive target for the treatment of cancer and inflammation. This paper is a follow-up to our previous studies, in which we report the structure-based design, synthesis, and evaluation of a new class of small-molecule BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold. The SARs focused on exploration of the 2′ or 3′ position to afford novel inhibitors that may avoid potential metabolically unstable site. The most potent inhibitor 13f exhibited high binding affinity to BRD4(1) with a ΔTm value of 7.8 °C as evaluated in thermal shift assay (TSA). The potent activity was also demonstrated by a peptide competition assay with an IC50 value of 0.21?μM. The docking studies revealed the binding mode of the compounds with the active site of BRD4(1). In addition, in silico predictions indicated that these compounds possessed good drug-likeness and pharmacokinetic profile. Graphic abstract: This paper is a follow-up to our previous studies, in which we report the structure-based design,synthesis, and evaluation of a new class of small-molecule BRD4 bromodomain inhibitors bearing a benzo[d]isoxazolscaffold.[Figure not available: see fulltext.].

Fused tetracyclic compound and application thereof in medicines

The invention relates to a fused tetracyclic compound and application thereof in medicines, in particular to application of the fused tetracyclic compound as a medicine for treating and/or preventing hepatitis B. Specifically, the invention relates to a c

Fused tetracyclic compound and application thereof in medicine

The invention relates to a fused tetracyclic compound and an application thereof in medicine, in particular to an application of a fused tetracyclic compound as a medicament for treating and/or preventing hepatitis B. More specifically, the present invention relates to a compound represented by general formula (I) or a stereoisomer thereof. Use of a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. The variables are as defined in the specification.

Green bromination method

The invention discloses a green bromination method, and belongs to the field of green organic chemistry. Under the conditions of room temperature, opening and neutrality, reaction raw materials are aromatic hydrocarbon, olefin, alkyne, tryptamine, tryptophane and derivatives thereof with different functional groups, a bromine source is MBrx (M is Fe , Fe , Ce and the like, and x is 2-3), and the unique oxidant is H2O2. Brominated alkanes, alkenes, aromatic hydrocarbons, pyrrolo-indolines and furo-indolines and derivatives thereof can be produced. The bromination reaction is carried out by using easily available and cheap reagents (such as FeBr2, CeB3 and H2O2) in the market and the solvent, and the method has the characteristics of mild reaction conditions, wide substrate application range, simple steps, easiness in operation and no need of separation, is a green, environment-friendly and safe bromination reaction method, and has a good application prospect.

Fused tetracyclic compounds and application thereof in medicines

The invention relates to fused tetracyclic compounds and an application thereof in medicines, and in particular, relates to the application of the fused tetracyclic compounds as medicines for treatingand/or preventing hepatitis B. Specifically, the invention relates to the compounds represented by a general formula (I) or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, wherein the variables are defined in the specification. The invention further relates to the application of the compounds represented by the general formula (I) or the stereoisomers, the tautomers, the nitric oxides, the solvates, the metabolites, the pharmaceutically acceptable salts or the prodrugs thereof as medicines, and in particular, relates tothe application of the compounds as the medicines for treating and/or preventing hepatitis B.

Method for synthesizing benzofuran heterocyclic sulfonyl chloride

The invention provides a method for synthesizing benzofuran heterocyclic sulfonyl chloride. The benzofuran heterocyclic sulfonyl chloride has a structural formula of a formula I shown in the specification. The method comprises the following steps: 1) by taking a compound 1, that is, 2,3-dihydrobenzofuran, as a raw material, and dichloromethane as a solvent, under catalysis of pyridine, performingelectrophilic addition on a benzene ring by using bromine so as to obtain a compound 2, that is, 5-2,3-dihydrobenzofuran; and 2) performing a chlorosulfonation reaction on a benzene ring by using a compound 2 through chlorosulfonic acid so as to obtain a compound of the formula I shown in the specification, that is, 5-2,3-dihydrobenzofuran-7-sulfonyl chloride, wherein the mole ratio of the compound 2 to the chlorosulfonic acid is 1:(2-20), the reaction temperature is 0-60 DEG C, and the reaction time is 0.5-12 hours. The preparation process of the derivative is not reported in either domesticor overseas documents at present. The invention designs a novel synthesis route, condition optimization is implemented for key reaction steps in the route, and optimal process conditions are confirmed. The novel process has the characteristics of being cheap in initial raw material, easy in initial raw material obtaining, short I step, easy in aftertreatment, high in yield, and the like, and is applicable to industrial production.

Intermolecular Aryl C?H Amination through Sequential Iron and Copper Catalysis

A mild, efficient and regioselective method for para-amination of activated arenes has been developed through a combination of iron and copper catalysis. A diverse range of products were obtained from an operationally simple one-pot, two-step procedure involving bromination of the aryl substrate with the powerful Lewis acid iron(III) triflimide, followed by a copper(I)-catalysed N-arylation reaction. This two-step dehydrogenative process for the regioselective coupling of aromatic C?H bonds with non-activated amines was applicable to anisole-, phenol-, aniline- and acetanilide-type aryl compounds. Importantly, the arene substrates were used as the limiting reagent and required no protecting-group manipulations during the transformation.

PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST

The present invention relates to a compounds represented by the formula. The compounds of the present invention have a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as pharmaceutical agents, for example, tachykinin receptor antagonists, agents for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases or central nerve diseases.

LEWIS ACID CATALYZED HALOGENATION OF ACTIVATED CARBON ATOMS

A practical and efficient method for halogenation of activated carbon atoms using readily available /V-haloimides and a Lewis acid catalyst has been disclosed. This methodology is applicable to a range of compounds and any halogen atom can be directly introduced to the substrate. The mild reaction conditions, easy workup procedure and simple operation make this method valuable from both an environmental and preparative point of view.

Lewis acid catalyzed highly selective halogenation of aromatic compounds

A simple and efficient procedure for the halogenation of aromatic compounds with NCS, NBS, NIS and NFSI in the presence of catalytic amount of ZrCl 4 is described. Chlorination, bromination, iodination and fluorination of various aromatic compounds are performed with high selectivity under mild reaction conditions. Georg Thieme Verlag Stuttgart.